Adma Biologics: Understanding The Risks Of Blood Plasma Collection

Oct. 24, 2022 3:00 PM ETADMA Biologics, Inc. (ADMA)5 Comments


  • Adma Biologics saw its share price reach an all-time low of $1.10 in October 2021.
  • The company is engaged in operating plasma donor centers and marketing and selling plasma derive therapies.
  • The company's revenues were up >90% year-on-year in Q222, but net loss still exceeded >$13.7m, and have exceeded $70m in each of 2020 and 2021.
  • Management has promised revenues of ~$300m and profits of $50 - $100m by 2024.
  • That looks to be a tough challenge. There's potentially triple-digit upside in play if these goals are met but this seems like a tricky industry in which far larger companies are struggling.
  • Looking for more investing ideas like this one? Get them exclusively at Haggerston BioHealth. Learn More »
plasma in a plastic bag

Kalinovskiy/iStock via Getty Images

Investment Overview

New Jersey-based Adma Biologics (NASDAQ:ADMA) looks to present an attractive investment opportunity at the present time - at least on some levels - but the downside risks are such that it's tricky to fully back the upside opportunity.

If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth. Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there.

This article was written by

Edmund Ingham profile picture
Receive regular, detailed analysis focused on biotech and healthcare stocks

I write about Biotech, Pharma and Healthcare stocks and share investment tips. Find me at my marketplace channel, Haggerston BioHealth - model portfolio + 4 exclusive stock tips every week. I'm on twitter @edmundingham

Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Recommended For You

Comments (5)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.